The use of 5-FU pharmacogenomics from paraffin blocks in patients with breast cancer receiving fluorouracil therapy

Abstract

The pyrimidine analog 5-fuorouracil (5-FU ) is a cytostatic drug that is widely used for the treatment of many solid carcinomas including breast cancer. More than 80 - 85% of administered 5-FU is quickly metabolized in the liver through a series of metabolic steps involving an enzyme dihydropirimidine dehydrogenase (DPD).

Keywords

• 5-Fluorouracil
• Breast carcinoma
• DPYD
• FFPET
• Pharmacogenomics
• Toxicity